What is Bioseal?
With a legacy spanning over 35 years, Bioseal has established itself as a critical partner for healthcare institutions, specializing in the provision of surgical put-ups, single-use instruments, and advanced infection control solutions. The company's product portfolio, which includes the proprietary Duraholder Instrument Protection System and BioView Scopes, is engineered to meet the rigorous demands of sterile processing managers and operating room directors. By focusing on custom procedural trays and high-quality manufacturing standards, Bioseal serves as a foundational pillar for hospital efficiency and patient safety protocols across the nation.
How much funding has Bioseal raised?
Bioseal has raised a total of $1.3M across 2 funding rounds:
Debt
$350K
Debt
$926K
Debt (2020): $350K with participation from PPP
Debt (2021): $926K led by PPP
Key Investors in Bioseal
PPP
Public-Private Partnership
What's next for Bioseal?
The recent influx of capital positions Bioseal to accelerate its enterprise-level growth strategy, likely focusing on the expansion of its custom manufacturing capabilities and the integration of next-generation surgical technologies. As the healthcare sector continues to prioritize infection control and streamlined sterile processing, Bioseal is well-positioned to capture additional market share. Future strategic initiatives will likely involve optimizing supply chain resilience and deepening relationships with major hospital networks, ensuring that their specialized instrument solutions remain at the forefront of clinical practice. The company's focus on quality management remains a key differentiator as it scales its operations to meet the evolving needs of modern surgical environments.
See full Bioseal company page
